Division of Nuclear Medicine and Molecular Imaging, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Boston, MA, 02115, USA,
Eur J Nucl Med Mol Imaging. 2014 Dec;41(12):2346-53. doi: 10.1007/s00259-014-2860-1. Epub 2014 Aug 6.
To determine if the minimum administered radiopharmaceutical activity for hepatobiliary scintigraphy can be reduced while preserving diagnostic image quality using enhanced planar processing (EPP).
A total of 40 infants between 10 and 270 days old (body mass 2.2 - 6.5 kg) had hepatobiliary scintigraphy during the period 2004 - 2010 following the intravenous administration of either (99m)Tc-mebrofenin (18 patients) or (99m)Tc-disofenin (22 patients). Due to the small size of these patients, they all received the minimum administered activity of 18.5 MBq consistent with the North American Consensus Guidelines. Six nuclear medicine physicians subjectively graded the acceptability of the image quality for clinical interpretation using a four-point scale (not acceptable, fair, good, excellent). Each physician independently graded seven image sets including the original study (full activity) and simulated reduced activity studies using binomial subsampling (50% of full activity, 25% of full activity and activity reduced by weight), with and without EPP.
For full-activity studies, 98% were deemed acceptable by the six physicians for clinical interpretation. The percentages of acceptable 50% reduced activity studies with and without EPP were not significantly different from the percentage of acceptable full-activity studies (P = 0.193 and P = 0.998, respectively). The percentage of acceptable 25% reduced activity studies without EPP was significantly different from the percentage of acceptable full-activity studies (P < 0.001); however, this difference vanished when EPP was applied (P = 0.482). The activity reduced by weight ranged from 1.85 to 4.81 MBq (10% to 26% of full dose) and the percentages of acceptable studies with and without EPP were significantly different from the percentage of acceptable full-activity studies (P < 0.001 and P = 0.02, respectively).
Clinically interpretable hepatobiliary scintigraphy images can be obtained in infants when the minimum administered activity is substantially reduced. Without EPP, clinically acceptable images may be produced with a reduction of 50%, and with EPP, a reduction of 75% or more may be possible.
使用增强平面处理(EPP),确定在保持诊断图像质量的同时,能否降低肝胆闪烁成像的最小放射性药物活度。
2004 年至 2010 年期间,40 名 10 至 270 天大(体重 2.2 至 6.5 公斤)的婴儿在静脉注射(99m)Tc-美罗芬宁(18 名患者)或(99m)Tc-双碘芬宁(22 名患者)后进行肝胆闪烁成像。由于这些患者体型较小,他们都接受了符合北美共识指南规定的最小放射性药物活度 18.5MBq。六位核医学医师使用四分制(不可接受、尚可、良好、极好)对图像质量的可接受性进行了主观评分,以便进行临床解释。每位医师分别对包括原始研究(全活度)和模拟减少活度研究(全活度的 50%、全活度的 25%和按体重减少的活度)在内的七个图像集进行了独立评分,这些研究集都有和没有 EPP。
对于全活度研究,六位医师均认为 98%的研究可用于临床解释。有和没有 EPP 的 50%减少活度研究中,可接受的研究百分比与全活度研究的百分比没有显著差异(P = 0.193 和 P = 0.998)。没有 EPP 的 25%减少活度研究的可接受百分比与全活度研究的百分比有显著差异(P < 0.001);然而,当应用 EPP 时,这种差异消失(P = 0.482)。按体重减少的活度范围为 1.85 至 4.81MBq(全剂量的 10%至 26%),有和没有 EPP 的可接受研究百分比与全活度研究的百分比有显著差异(P < 0.001 和 P = 0.02)。
在大幅度减少最小放射性药物活度的情况下,仍可获得可用于临床解释的婴儿肝胆闪烁成像图像。如果不使用 EPP,则可通过减少 50%来获得可接受的临床图像,而如果使用 EPP,则可减少 75%或更多。